Financial Data and Key Metrics Changes - Revenue in Q4 2025 was $62.5 million, a decrease of 9% compared to the prior year period, primarily due to a shift in revenue mix towards lower-priced products [21] - Gross margin was 80.6% in Q4 2025, slightly down from 80.7% in Q4 2024 [21] - The net loss for Q4 2025 was $9.4 million, or $0.15 per share, compared to a net loss of $0.5 million, or $0.01 per share, in Q4 2024 [22] - Full year 2025 adjusted EBITDA loss was $3.9 million, a 64% improvement over the prior year [22] - Cash usage for the full year 2025 was $27.3 million, a 46% reduction compared to $50.5 million in 2024 [23] Business Line Data and Key Metrics Changes - The company has expanded its bunion procedure offerings, now addressing virtually 100% of surgeons' technique preferences with five best-in-class instrumented systems [5] - The new bunion systems launched in 2025 have already been adopted by over 25% of the surgeon base, contributing to increased procedure volume growth [13] - The company expects to continue to reduce cash burn by approximately 50% in 2026 compared to 2025 [9] Market Data and Key Metrics Changes - The overall foot and ankle market was reported to be unusually soft in 2025, with elective procedures experiencing declines [27] - The company anticipates that case volume growth will improve in 2026, particularly in the fourth quarter, driven by new product launches and an increase in case volumes [8][19] Company Strategy and Development Direction - The company is focused on leveraging its existing customer base to drive adoption of new bunion products and expanding its product offerings to grow wallet share [10] - The introduction of new technologies, such as the Lapiplasty Lightning and SpeedTMT, is expected to attract new surgeons and enhance the company's competitive position [15][19] - The company plans to continue its emphasis on medical education and training for surgeons to ensure successful integration of new products [18] Management's Comments on Operating Environment and Future Outlook - Management noted that while there are ongoing headwinds related to economic conditions and consumer sentiment, they remain confident in their strategies to restore revenue growth [7] - The outlook for full year 2026 revenue is projected to be in the range of $200 million to $212 million, reflecting a decline of 6% to 0% compared to 2025 [8][23] - Management expressed optimism about the potential for market share gains and improved profitability through disciplined investments and strategic initiatives [19] Other Important Information - The company has expanded its active surgeon base from nearly 1,300 users in 2020 to over 3,300 users in 2025, indicating strong growth in customer engagement [18] - The company has entered the biologics market with new offerings, which are expected to enhance revenue without negatively impacting margins [16] Q&A Session Summary Question: Insights on the softness in the foot and ankle market - Management acknowledged that 2025 was a softer year for elective procedures, but noted an increase in Q4 case volumes, indicating market share gains despite the overall market conditions [27] Question: Impact of the biologics portfolio on operating margins - Management expressed confidence that the expansion into biologics would provide additional revenue without negatively impacting margins [30] Question: Development timeline and surgeon feedback on new products - Management confirmed that new products like SuperBite screws and SpeedXM have been in development for about 18 months and received positive feedback from surgeons during testing [35] Question: Guidance assumptions for 2026 - Management indicated that guidance includes assumptions for the uptake of new products and the performance of existing offerings, with a focus on achieving reasonable and achievable targets [82] Question: Strategy for penetrating the market - Management emphasized the strategy of deepening engagement with the existing surgeon base while also attracting new surgeons through innovative product offerings [88]

Treace Medical Concepts FY Conference Summary Company Overview - **Company**: Treace Medical Concepts (NasdaqGS:TMCI) - **Industry**: Medical Device, specifically focused on bunion correction - **Mission**: Improve surgical outcomes for bunion patients through innovative technologies - **IPO**: 2021, with significant market share gains and Adjusted EBITDA progress since then [1][2] Core Points and Arguments Market Position and Strategy - Treace Medical is the largest dollar share player in the U.S. bunion market, having transformed from a Lapiplasty company to a comprehensive bunion solutions provider [2][6] - The bunion market is considered under-penetrated, with approximately 4.5 million Americans seeking treatment annually, and an estimated $5 billion-plus U.S. Total Addressable Market (TAM) [3][17] - Less than half of symptomatic surgical candidates opt for surgery due to past surgical downsides, indicating a significant opportunity for Treace's innovative solutions [3][10] Product Innovations - Introduction of the **Lapiplasty 3D Bunion Correction Procedure** has revolutionized bunion surgery by addressing all three planes of bunion deformity, leading to better surgical outcomes [4][5] - New technologies such as **Nanoplasty** and **Percuplasty** target high-volume osteotomy segments, representing 70% of annual bunion cases in the U.S. [8][9] - The **Speed MTP system** addresses arthritic great toe or MTP joints, expanding Treace's offerings in the bunion market [9][10] Financial Performance - In Q4, revenues were projected between $62.1 million and $62.5 million, slightly above market expectations, driven by robust uptake of new technologies [19][20] - Adjusted EBITDA improved by 55% year-over-year in 2024, with expectations for continued profitability in Q4 2025 and significant cash usage reduction [18][45] - Surgeon customer base grew from nearly 1,300 in 2020 to over 3,300 in 2025, achieving a 21% CAGR [17] Market Trends and Challenges - Variability in patient scheduling and softer demand were noted in 2025, impacting overall market trends [21][22] - Surgeons expressed excitement about new MIS technologies, which are expected to reduce learning curves and improve adoption rates [23][24] - The company aims to penetrate the remaining 75% of cases within existing surgeon accounts by leveraging its expanded product portfolio [9][32] Future Outlook - Plans for 2026 include the commercialization of the next-generation **Lapiplasty Lightning**, which aims to enhance surgical efficiency and accuracy [12][41] - The company is focused on expanding its sales force and enhancing its direct sales strategy, which currently accounts for about 75% of revenue [40] - Continued emphasis on medical education and training for surgeons to ensure successful adoption of new technologies [46][47] Additional Important Insights - Treace Medical's commitment to innovation and comprehensive solutions positions it well in a growing market, with a focus on minimally invasive procedures that appeal to both surgeons and patients [10][11] - The company is strategically adding complementary technologies to enhance its offerings and increase customer wallet share over time [14][15] - The introduction of new products is expected to drive volume growth, with aspirations to significantly increase market penetration in the bunion surgery segment [35][39]